MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329208 | Name: Cabergoline
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cabergoline, also known as Cabaser and CG-101, is a dopamine D2 receptor agonist used for prolactinoma treatment. Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels.

Chemical Structure

Cabergoline
Cabergoline
CAS#81409-90-7 (free base)

Theoretical Analysis

MedKoo Cat#: 329208

Name: Cabergoline

CAS#: 81409-90-7 (free base)

Chemical Formula: C26H37N5O2

Exact Mass: 451.2947

Molecular Weight: 451.62

Elemental Analysis: C, 69.15; H, 8.26; N, 15.51; O, 7.09

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
50mg USD 995.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
81409-90-7 (free base) 85329-89-1 (phosphate)
Synonym
Cabergoline; CG-101; FCE-21336; CG 101; FCE 21336; CG101; FCE21336; Cabaser; Cabaseril
IUPAC/Chemical Name
(6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
InChi Key
KORNTPPJEAJQIU-KJXAQDMKSA-N
InChi Code
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
SMILES Code
O=C(NCC)N(C([C@H](C[C@@]12[H])CN(CC=C)[C@]1([H])CC3=CNC4=C3C2=CC=C4)=O)CCCN(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2939.69.0000
More Info
Certificate of Analysis
View CoA: current batch, Lot# T8R12C07
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 451.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gadelha MR, Wildemberg LE, Shimon I. Pituitary acting drugs: cabergoline and pasireotide. Pituitary. 2022 Oct;25(5):722-725. doi: 10.1007/s11102-022-01238-8. Epub 2022 Jun 7. PMID: 35670988. 2: Greenman Y, Bronstein MD. Cabergoline should be attempted in progressing non- functioning pituitary macroadenoma. Eur J Endocrinol. 2021 Aug 27;185(4):D11-D20. doi: 10.1530/EJE-21-0344. PMID: 34288884. 3: Tulloch KJ, Dodin P, Tremblay-Racine F, Elwood C, Money D, Boucoiran I. Cabergoline: a review of its use in the inhibition of lactation for women living with HIV. J Int AIDS Soc. 2019 Jun;22(6):e25322. doi: 10.1002/jia2.25322. PMID: 31183987; PMCID: PMC6558502. 4: Inder WJ, Jang C. Treatment of Prolactinoma. Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095. PMID: 36013562; PMCID: PMC9413135. 5: Harris K, Murphy KE, Horn D, MacGilivray J, Yudin MH. Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review. J Obstet Gynaecol Can. 2020 Mar;42(3):308-315.e20. doi: 10.1016/j.jogc.2019.03.014. Epub 2019 Jul 6. PMID: 31285168. 6: Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008605. doi: 10.1002/14651858.CD008605.pub2. Update in: Cochrane Database Syst Rev. 2016 Nov 30;11:CD008605. PMID: 22336848. 7: Miceli DD, García JD, Pompili GA, Rey Amunategui JP, Ferraris S, Pignataro OP, Guitelman M. Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism. J Feline Med Surg. 2022 Dec;24(12):1238-1244. doi: 10.1177/1098612X221074924. Epub 2022 Feb 8. PMID: 35133181. 8: Mönig H, Krack P. Cabergolin [Cabergoline]. Dtsch Med Wochenschr. 1998 Nov 6;123(45):1349-50. German. doi: 10.1055/s-0029-1237286. PMID: 9835894. 9: De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz. 2013 Dec;38(8):868-80. doi: 10.1007/s00059-013-3816-0. Epub 2013 Jun 8. PMID: 23743769. 10: Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta- analysis of randomized controlled trials. Fertil Steril. 2014 Mar;101(3):664-75. doi: 10.1016/j.fertnstert.2013.11.005. Epub 2013 Dec 18. PMID: 24360566. 11: Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2001;2001(1):CD001518. doi: 10.1002/14651858.CD001518. PMID: 11279720; PMCID: PMC8406784. 12: Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: 10.1159/000495775. Epub 2019 Mar 18. PMID: 30481756. 13: dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011 Sep;14(3):259-65. doi: 10.1007/s11102-010-0290-z. PMID: 21221817. 14: Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008 Oct;159(4):363-7. doi: 10.1530/EJE-08-0611. Epub 2008 Aug 14. PMID: 18703568. 15: Lin S, Zhang A, Zhang X, Wu ZB. Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology. 2020;110(6):477-488. doi: 10.1159/000504000. Epub 2019 Oct 10. PMID: 31597135. 16: Humphrey S, Baechler M, Schiff M, Hitti J. Cabergoline for postpartum lactation suppression: Effect on blood pressure and pulse. Int J Gynaecol Obstet. 2022 Dec;159(3):776-782. doi: 10.1002/ijgo.14184. Epub 2022 Apr 8. PMID: 35304744. 17: Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2001;2001(1):CD001519. doi: 10.1002/14651858.CD001519. PMID: 11279721; PMCID: PMC8406454. 18: Ferrari C, Piscitelli G, Crosignani PG. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod. 1995 Jul;10(7):1647-52. doi: 10.1093/oxfordjournals.humrep.a136149. PMID: 8582955. 19: Curran MP, Perry CM. Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. doi: 10.2165/00003495-200464180-00015. PMID: 15341508. 20: Hacisahinogullari H, Yalin GY, Selcukbiricik OS, Gul N, Bilgic B, Uzum AK, Tanakol R, Aral F. Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients. Horm Metab Res. 2022 Oct;54(10):664-670. doi: 10.1055/a-1930-6585. Epub 2022 Oct 7. PMID: 36206759.